Main Menu

Spring Bank Pharmaceuticals, Inc.



Attention investors who purchased shares of Spring Bank Pharmaceuticals, Inc. before July 29, 2020:

Rigrodsky & Long is investigating potential claims against the board of directors of Spring Bank Pharmaceuticals, Inc. concerning possible breaches of fiduciary duty and other violations of law related to the Company’s agreement to acquire F-star Therapeutics Limited.

Press Release

Rigrodsky & Long, P.A. announces that it is investigating Spring Bank Pharmaceuticals, Inc. (“Spring Bank”) (NASDAQ GS: SBPH) regarding possible breaches of fiduciary duties and other violations of law related to Spring Bank’s agreement acquire F-star Therapeutics Limited (“F-star”).  Under the terms of the agreement, shareholders of Spring Bank will own approximately 38.8% of the combined company while F-star holders will own approximately 61.2% of the combined company.

If you would like to discuss this investigation and your rights cost and obligation free, please contact Seth D. Rigrodsky or Gina M. Serra toll free at (888) 969-4242 or by e-mail at 

Rigrodsky & Long, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in securities fraud and corporate class actions nationwide.

Attorney advertising.  Prior results do not guarantee a similar outcome.

Back to Page